Aslan Pharmaceuticals Ltd Stock Revenue
| ASLN Stock | USD 0.47 0.01 2.17% |
Aslan Pharmaceuticals Ltd fundamentals help investors to digest information that contributes to Aslan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aslan Stock. The fundamental analysis module provides a way to measure Aslan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aslan Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 13.8 M | 14.5 M |
Aslan | Revenue |
Aslan Pharmaceuticals Ltd Company Revenue Analysis
Aslan Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Aslan Pharmaceuticals Revenue | 12 M |
Most of Aslan Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aslan Pharmaceuticals Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Aslan
Projected quarterly revenue analysis of Aslan Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Aslan Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Aslan Pharmaceuticals' stock price.
Aslan Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Aslan Pharmaceuticals is extremely important. It helps to project a fair market value of Aslan Stock properly, considering its historical fundamentals such as Revenue. Since Aslan Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aslan Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aslan Pharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Aslan Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Aslan Pharmaceuticals Ltd reported 12 M of revenue. This is 99.84% lower than that of the Biotechnology sector and 98.38% lower than that of the Health Care industry. The revenue for all United States stocks is 99.87% higher than that of the company.
Aslan Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aslan Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics of similar companies.Aslan Pharmaceuticals is currently under evaluation in revenue category among related companies.
Aslan Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Aslan Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aslan Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aslan Pharmaceuticals' value.| Shares | Waterfront Wealth Inc. | 2023-12-31 | 40.9 K | Ikarian Capital, Llc | 2023-12-31 | 35.4 K | Xtx Topco Ltd | 2023-12-31 | 27.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 24.7 K | Jane Street Group, Llc | 2023-12-31 | 23.1 K | Onyx Bridge Wealth Group Llc | 2023-12-31 | 22.7 K | Temasek Holdings Ltd. | 2023-12-31 | 15.7 K | Capital Analysts Inc. | 2023-12-31 | 2 K | Rhumbline Advisers | 2023-12-31 | 1.3 K | Tang Capital Management Llc | 2023-09-30 | 1.9 M | Bvf Inc | 2023-09-30 | 1 M |
Aslan Fundamentals
| Return On Equity | -4.27 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (3.64) % | ||||
| Current Valuation | 262.95 M | ||||
| Shares Outstanding | 22.63 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Shares Owned By Institutions | 15.48 % | ||||
| Number Of Shares Shorted | 116.78 K | ||||
| Price To Earning | (11.50) X | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 12 M | ||||
| Gross Profit | 79.82 M | ||||
| EBITDA | (43.39 M) | ||||
| Net Income | (44.22 M) | ||||
| Cash And Equivalents | 78.12 M | ||||
| Cash Per Share | 1.12 X | ||||
| Total Debt | 26.83 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 6.97 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (46.36 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (2.75) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 10.61 M | ||||
| Total Asset | 24.63 M | ||||
| Retained Earnings | (321.07 M) | ||||
| Working Capital | 11.02 M | ||||
| Current Asset | 54.61 M | ||||
| Current Liabilities | 5.15 M | ||||
| Net Asset | 24.63 M |
About Aslan Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aslan Pharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aslan Pharmaceuticals Piotroski F Score and Aslan Pharmaceuticals Altman Z Score analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.729 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.